StockNews.AI
GKOS
StockNews.AI
208 days

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

1. Glaukos plans to release Q4 and full year 2024 results on February 20, 2025. 2. A conference call will discuss financial results, indicating transparency to investors. 3. The iDose® TR launch in 2024 enhances Glaukos' innovative drug delivery offerings. 4. Glaukos markets FDA-approved therapies, positioning itself strongly in the ophthalmic space.

Earnings
-0.64%Current Return
VS
+0.27%S&P 500
$160.1201/23 07:14 AM EDTEvent Start
$159.0901/24 01:51 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report may show positive growth, influencing investor confidence, similar to past performance after earnings releases.

How important is it?

The article's focus on earnings and product launches is highly significant for GKOS's market perception.

Why Long Term?

Ongoing innovations and FDA-approved treatments could drive sustained revenue growth over time, as seen in similar companies post-launch.

Related Companies

GKOS
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20, 2025. A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Related News